Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
1 study · 22 participants
GRADE not reported
Investigator‐ or physician‐rated global assessment of disease severity · People with erosive oral lichen planus
Betamethasone oral mini-pulse therapy led to higher physician Global Assessment (clinical severity, 0-12 score) compared with topical triamcinolone acetonide 0.1% paste; GRADE not reported.
1 finding from 1 review
Participant's global assessment of improvement Non‐standardised scale5 · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Lesion count · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Blistering or scarring · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Thermotherapy one session (at 50 ºC for 30 seconds) leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg Sb5/kg/day (high certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death Number of deaths over 36 months · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Overall response rate (ORR), · stage III and IV cutaneous melanoma
1 finding from 1 review
Time to recurrence · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Other therapies (cryotherapy) changes short‐term hair regrowth ≥ 75% compared with other therapies (fractional CO2 laser) (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review